Prevention and Treatment of Multiple Sclerosis (MS) by Administering E-Selectin
Posted Jun 15 2010 5:00pm
Description of Invention: The invention is a method and composition for inhibiting or treating symptoms of inflammatory demyelination or inflammation associated with autoimmune disorders. This is accomplished by administering recombinant E-selectin protein intranasally and resulting in E selectin-specific regulatory T-cells. These regulatory T-cells suppress activation of blood vessels where E-selectin is normally expressed by the localized production of immunosuppressive cytokines, modulating the actions of otherwise pro-inflammatory T cells that can aberrantly cause demyelination of neurons, which leads to diseases like MS.
Applications: In addition to MS, potentially effective in treating other autoimmune disorders such as rheumatoid arthritis, type 1 diabetes, psoriasis, and those that affect blood vessels.
Development Status: In vitro and in vivo data are available.
Licensing Status: Available for non-exclusive or exclusive licensing.
Portfolios: Central Nervous System Central Nervous System - Therapeutics In-vivo Data In-vitro Data
For Additional Information Please Contact: Norbert Pontzer Ph.D., J.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325
Room 23, Rockville, MD 20852 United States Email: email@example.com Phone: 301-435-5502 Fax: 301-402-0220